Treatment with immunotherapy targeting checkpoint inhibitors PD-1 or CTLA-4 significantly increases survival in patients with metastatic melanoma over other standards of care [1, 2], with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4]. Here, CTLA4 is linked to metastatic melanoma.